EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proton treatment-plan dose verification with a DPM-based Monte Carlo engine

Aimee L. McNamara, Daniel O’Brien, Alan Nelson

Frontiers in Oncology · 06.11.2026 · 16

DOI: 10.3389/fonc.2026.1963150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 06.11.2026. Verfasst von Aimee L. McNamara und 2 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Independent proton dose verification requires a calculation pathway that is accurate enough to identify clinically relevant discrepancies while remaining practical to commission and operate. We use a pre-release version of the commercial RadMonteCarlo, a multithreaded CPU-based proton Monte Carlo engine built on a dose planning method (DPM) framework for independent treatment-plan recalculation. In this study, we evaluate the sensitivity of RadMonteCarlo to the conversion of CT Hounsfield units (HU) to relative stopping power (RSP).

Methods

RadMonteCarlo was commissioned from integrated depth-dose (IDD) curves, spot profiles, and absolute-output data for a pencil beam scanning proton system. Three HU-to-RSP assignments were evaluated: a density-derived parameterization, a Bethe–Bloch-based calculation, and a Schneider stoichiometric tissue model. Four anonymized clinical plans (prostate, bladder, lung, and brain) were recalculated. RadMonteCarlo dose was compared with the RayStation Monte Carlo dose, using three-dimensional gamma criteria of 3%/3 mm and 2%/ 2 mm. RadMonteCarlo distributions were also compared directly to isolate RSP sensitivity from TPS agreement.

Results

The commissioned fits achieved a mean R² of 0.9998, and re-simulated R80 values agreed with the measurements within 1 mm (mean difference +0.39 mm). All 12 clinical plan–RSP comparisons met the specified 95% criterion at 3%/3 mm. In direct RSP model comparisons, target mean-dose differences ranged from−1.15% to +1.20%, distal R80 shifts along the beam axes ranged from−0.3 to +1.9 mm, and the 95th-percentile absolute voxelwise dose difference ranged from 1.8% to 4.1%.

Discussion

These controlled comparisons demonstrate that HU-to-RSP selection produces localized, anatomy- and beam-path- dependent changes in the individual cases examined. RadMonteCarlo therefore provides a stable independent recalculation framework in which calibration-driven effects can be identified and interpreted separately from transport or source-model differences.

Zitieren

APA

McNamara, A. L., O’Brien, D., & Nelson, A. (2026). Proton treatment-plan dose verification with a DPM-based Monte Carlo engine. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1963150

Vancouver

McNamara AL, O’Brien D, Nelson A. Proton treatment-plan dose verification with a DPM-based Monte Carlo engine. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1963150

BibTeX
@article{McNamara2026,
  author = {McNamara, Aimee L. and O’Brien, Daniel and Nelson, Alan},
  title = {Proton treatment-plan dose verification with a DPM-based Monte Carlo engine},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1963150}
}
Kostenlos starten →